Crohn's Disease High Risk Life Insurance Quotes

Crohn’s disease is a chronic inflammatory bowel condition that underwriters evaluate primarily on disease activity, treatment history, and whether the condition is in remission. Mild-to-moderate Crohn’s in documented remission — no recent flares, no hospitalizations, no biologic therapy — can qualify for standard or near-standard rates at several carriers. Active, severe disease with frequent flares or recent surgery will result in table ratings or, in some cases, a decline.

What Underwriters Evaluate for Crohn’s Disease

Underwriters look at multiple dimensions of Crohn’s history to assess risk. Key factors include:

Disease Activity and Remission Status — Whether Crohn’s is in clinical remission is the single most important factor. Remission supported by normal lab work, stable weight, no flares in the past 1–2 years, and a normal colonoscopy is the most favorable profile. Active disease with ongoing symptoms is rated much more harshly.

Flare Frequency and Severity — Underwriters want to know how often flares occur and how severe they are. A single isolated flare years ago with no recurrence is very different from monthly or bimonthly flares requiring treatment. Frequency trends over time matter — improving or stable is positive; worsening is negative.

Medication Type and Level of Treatment — Medications indicate disease severity. Aminosalicylates (mesalamine) suggest mild disease. Immunomodulators (azathioprine, 6-MP, methotrexate) indicate moderate disease. Biologic therapies (Humira, Remicade, Stelara, Skyrizi) signal more significant disease. Corticosteroid dependence is viewed negatively.

Hospitalizations and Surgeries — Any hospitalization or bowel surgery (resection, strictureplasty, ostomy) significantly increases the underwriting risk. Recent surgeries within the past 1–2 years are particularly impactful. A long post-surgical period with stable remission is more favorable than a recent procedure.

Lab Work and Colonoscopy Results — Normal or near-normal CRP, ESR, fecal calprotectin, and CBC are strong favorable indicators. Normal colonoscopy findings showing mucosal healing are excellent supporting evidence for remission. Active inflammation or dysplastic lesions on colonoscopy raise significant concern.

Weight and Nutritional Status — Significant or progressive unintentional weight loss signals active, uncontrolled disease. Maintaining a healthy, stable weight is a positive underwriting factor and suggests the disease is well-managed.

Complications and Extraintestinal Manifestations — Fistulas, abscesses, strictures, perianal disease, or extraintestinal complications (joint involvement, uveitis, skin manifestations) all increase the risk profile. These indicate more aggressive, systemic disease.

Co-Morbid Conditions — Crohn’s combined with other conditions such as diabetes, anemia, malabsorption disorders, or mental health issues increases the overall risk and can push an otherwise-rateable case into a decline.

Carrier Guidelines: Crohn’s Disease Underwriting Comparison

The table below reflects how major carriers generally approach Crohn’s disease underwriting. Best outcomes are achievable for well-documented remission cases.

Carrier	Mild / In Remission (No Biologics)	Moderate / On Biologics	Active Disease / Recent Hospitalization	Severe / Frequent Flares or Recent Surgery
Protective Life	Standard to Table 2 (best-case Standard for single mild episode, long remission)	Table 2–6	Table 6–8 or Decline	Decline
Banner Life / Legal & General	Standard to Table 2	Table 2–6	Table 6–8 or Decline	Decline
Prudential	Standard possible for mild, documented remission; otherwise Table 2–4	Table 4–6	Table 6–8 or Decline	Decline
Pacific Life	Standard to Table 2	Table 2–6	Table 6 or Decline	Decline
North American Company	Standard to Table 2	Table 2–6	Table 6–8 or Decline	Decline
Mutual of Omaha	Standard to Table 2	Table 2–6	Table 6–8 or Decline	Decline
Lincoln Financial	Standard to Table 2	Table 2–6	Table 6–8 or Decline	Decline
Transamerica	Standard to Table 2	Table 2–6	Table 6–8 or Decline	Decline

Guidelines current as of 2025–2026. Carrier underwriting guidelines are subject to change. Verify with us before applying.

Presentations/Situations That Are Typically Declined

Some Crohn’s disease presentations are difficult or impossible to place at traditional fully-underwritten carriers:

Active Crohn’s with Ongoing Flares — Disease that is not in remission, with ongoing symptoms and frequent flares, is typically declined at most traditional fully-underwritten carriers until a documented period of stability is achieved.

Recent Bowel Surgery (Within 1–2 Years) — A recent bowel resection, ostomy, or other intestinal surgery is a significant negative factor. Most carriers require a waiting period post-surgery to assess whether the intervention produced lasting remission before they will consider coverage.

Fistulizing or Perforating Disease — Crohn’s with fistulas, abscesses, or perforations indicates aggressive, penetrating disease behavior. This significantly increases mortality risk assessment and often leads to a decline at standard carriers.

Multiple Hospitalizations in Recent Years — Multiple hospitalizations within the past 2–3 years for Crohn’s-related complications demonstrate a severe, poorly controlled disease course that most carriers are unwilling to underwrite at standard rates.

Chronic Corticosteroid Dependence — Long-term or frequent corticosteroid use (prednisone, budesonide) indicates inability to maintain remission with standard therapies and is a strong negative signal to underwriters. It also creates secondary health risks such as bone density loss and metabolic issues.

Significant Malnutrition or Unintentional Weight Loss — Ongoing unintentional weight loss or significant malnutrition due to active Crohn’s signals that the disease is severely impacting quality of life and overall health. This is typically a decline indicator at most carriers.

What You Can Do to Improve Your Outcome

Achieve and Document Remission — The most important step is achieving and documenting clinical remission. Work with your gastroenterologist to obtain lab work, colonoscopy results, and a clinical note confirming remission status. This documentation is your single best underwriting asset.

Maintain Regular GI Follow-Ups — Ongoing specialist care with documented stable follow-ups demonstrates that the disease is being actively monitored. Gaps in gastroenterologist care are viewed negatively by underwriters.

Stay on Your Medication Regimen — Whether you take aminosalicylates, immunomodulators, or biologics, consistent adherence to your prescribed treatment plan signals to underwriters that you are proactively managing the condition. Do not stop medications without physician guidance.

Maintain a Healthy Weight — Stable weight — ideally within a normal BMI range — is a positive indicator that your Crohn’s is under control and not causing nutritional deficiencies. Even modest weight stabilization after a period of loss can improve your profile.

Avoid Smoking and Alcohol — Smoking is a significant risk factor for Crohn’s flares and is known to worsen disease activity. Underwriters view smoking very negatively for Crohn’s applicants. Alcohol can also trigger flares and should be minimized.

Work with a Specialist Broker — Crohn’s underwriting varies significantly between carriers — what one carrier rates at Table 4 another may offer at Standard for the same applicant in documented remission. A specialist broker who informally shops your profile across 10–15 carriers can identify the best available rate without triggering formal applications or impacting your insurability. Learn more about how TIB works.

Have Crohn’s Disease? Let’s Find the Right Carrier.

Crohn’s underwriting is highly individualized. We informally shop your profile across 10–15 top-rated carriers to find the best available rate — without triggering formal applications or impacting your insurability.

📞 Call 1-888-972-0024
Get an Instant Quote →

Browse All High-Risk Conditions

Understanding Your Rating:
Life Insurance Risk Classifications |
Table Ratings Explained (B–J) |
Flat Extra Ratings

Authoritative Resources: Life insurance underwriting practices are regulated by the NAIC. Insurers may check your health history through the MIB Group — you can request your free annual MIB report at mib.com.

Frequently Asked Questions

What rate class can I get for life insurance with Crohn’s disease?

Rate class depends on disease severity, control, and treatment response. Mild Crohn’s in sustained remission on stable therapy typically qualifies for Standard or Standard Plus rates. Moderate Crohn’s with occasional flares, biologic therapy, or history of surgical resection usually results in Table 2 to Table 4 ratings. Severe or active Crohn’s with frequent flares, ongoing complications (fistulas, strictures, abscesses), or recent hospitalizations often results in Table 4 through Table 6 ratings, and Preferred rates are generally not available regardless of control.

How does biologic therapy for Crohn’s affect life insurance underwriting?

Being on biologic therapy (Humira, Remicade, Stelara, Entyvio, Skyrizi) is not itself a negative — it often signals well-controlled disease. Carriers view documented response to biologics favorably compared to flares on conventional therapy. What matters most is current disease activity, stability of response, and absence of complications. Some carriers now offer Standard Plus rates to applicants with well-controlled Crohn’s on stable biologic therapy for 2 or more years, which represents a significant improvement from a decade ago.

Do surgical resections for Crohn’s disease affect underwriting?

History of surgical resection is noted but often does not worsen underwriting if the post-surgical course has been stable. A single resection followed by sustained remission may actually underwrite better than multiple flares without surgery. Multiple resections, short bowel syndrome, or ostomy typically results in higher table ratings (Table 4 through Table 6) due to nutritional and complication risk. Carriers look for at least 12 months of post-surgical stability before offering best available rates.

Does Crohn’s disease increase cancer risk that affects life insurance?

Yes, slightly. Long-standing Crohn’s disease, especially with colonic involvement of 10 or more years, carries modestly increased colorectal cancer risk, which underwriters factor in. Applicants with documented surveillance colonoscopies (typically every 1 to 3 years for long-standing Crohn’s) and no dysplasia findings see minimal impact. A history of dysplasia or cancer adds a separate underwriting layer on top of the Crohn’s rating itself.

What’s the best way to strengthen my Crohn’s life insurance application?

Three factors matter most: demonstrated disease stability (12+ months without flares), documented treatment compliance and response (clinic notes showing stable biologic therapy with therapeutic drug levels if available), and absence of complications in recent workup. Having a current gastroenterologist letter stating disease is in remission, along with recent labs and imaging, strengthens the application substantially. Applying during a stable period rather than shortly after a flare or medication change typically produces a one to two rate-class improvement.

Crohn’s Disease High Risk Life Insurance Quotes